
NEJM to Publish Savara’s Phase 3 IMPALA-2 Trial Results in Autoimmune PAP
Savara’s Landmark IMPALA-2 Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis to Be Published in The New England Journal of Medicine Savara Inc. (Nasdaq: SVRA), a clinical-stage…











